AstraZeneca creates $1B Chinese fund, vows to double R&D team

AstraZeneca is stepping up its commitment to China, detailing plans to double the head count at its Shanghai R&D site and create a $1 billion investment fund. The initiatives build on the rapid growth AstraZeneca has achieved in China in recent years.